Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

The company achieved several key pipeline milestones, including the approval of Jaypirca in the EU for CLL and Omvoh in the US, EU, and Japan for Crohn's disease. Eli Lilly and Co (NYSE ...

Thank you for joining us for Eli Lilly & Company's Q1 2025 earnings call ... Our key products defined as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound grew by more than ...

Eli Lilly and Co (LLY) reports a 45% revenue increase, driven by key products and strategic advancements in diabetes and ...